Opendata, web and dolomites

PCSP

Odour-GPCRs based technology for detection and stratification of cancer: Prostate Cancer Smell Print as first vertical market

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PCSP project word cloud

Explore the words cloud of the PCSP project. It provides you a very rough idea of what is the project "PCSP" about.

technology    stress    anxiety    percentage    transferring    trained    diagnostic    receptors    urine    acquisition    cells    nose    pca    risky    heterologous    prototype    care    scenarios    detecting    invasive    activation    extension    penetration    technologies    expression    readable    olfactory    accuracy    detect    analysed    producing    quantify    points    tested    coupling    ogpcrs    dogs    physicians    compounds    cascade    array    false    gain    appreciable    saving    negatives    broad    biotech    standard    patients    diagnosis    identification    trial    pcsp    recognition    feasibility    organic    resembles    born    subject    showed    canvax    prostate    appropriate    amount    fluorescent    print    unnecessary    ideal    signalling    adoption    cover    discrimination    clinic    clinical    ed    validation    screening    positives    pretends    accurate    definition    patented    owns    dog    samples    cancer    market    selling    difficult    regulatory    financial    antigen    volatile    initial    smell    ogpcr    expressing    unmet    types    permits    assays    universal    scalable    detection    expertise   

Project "PCSP" data sheet

The following table provides information about the project.

Coordinator
CANVAX BIOTECH SL 

Organization address
address: POLIG TECNOCORDOBA CL 14 E PARC 47 PLANTA 2
city: CORDOBA
postcode: 14014
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://canvaxbiotech.com/canvax-is-awarded-with-phase-i-sme-instrument-h2020/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CANVAX BIOTECH SL ES (CORDOBA) coordinator 50˙000.00

Map

 Project objective

PCSP project is born out of the unique expertise developed after years of R&D at Canvax Biotech, and aims at transferring a technology to cover an unmet clinical need, accurate diagnosis of prostate cancer (PCa). Canvax owns a unique set of patented technologies: i) high expression of olfactory receptors (oGPCRs) in heterologous cells, ii) coupling to a signalling cascade and iii) readable fluorescent assays to quantify oGPCR activation. Canvax is producing an array of cells expressing oGPCRs that could be used to detect several types of cancer, including PCa, by detecting cancer-associated volatile organic compounds in urine. The technology is currently being tested in a PCa clinical trial. PCa detection has been widely carried out using the prostate specific antigen test. However, its low accuracy resulted in a high percentage of false positives and a still appreciable amount of false negatives. Several recent studies showed that trained dogs could detect PCa from urine samples with the higher accuracy. However, the use of dogs in clinic is difficult and non-scalable. Canvax PCSP test resembles a dog nose that pretends to be a universal screening method for PCa-type discrimination identifying, in simple urine test, patients in need of further, more invasive diagnostic procedures with higher accuracy than current standard of care, saving stress, anxiety and unnecessary risky procedures. The easy use and low cost of this technology makes it ideal for broad adoption. Different scenarios have been described for market penetration and would be subject of the feasibility study during phase I: Smell print definition, regulatory and market permits acquisition, clinical trial design, identification of best-selling points, EU extension and financial costs will be analysed. The appropriate measures will be applied during phase II, together with prototype validation in a large clinical trial to gain recognition within the physicians, and initial exploitation of the technology

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PCSP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PCSP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

FURTHER (2019)

Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone Metastasis

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More